You are here

Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses.

TitleNitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses.
Publication TypeJournal Article
Year of Publication2011
AuthorsGiordano, D, Li, C, Suthar, MS, Draves, KE, Ma, DY, Gale, M, Clark, EA
JournalJ Leukoc Biol
Volume89
Issue3
Pagination443-55
Date Published2011 Mar
ISSN1938-3673
KeywordsAnimals, Antigens, CD86, Antigens, Ly, Antigens, Surface, Apoptosis Regulatory Proteins, Biological Markers, CD4-Positive T-Lymphocytes, Cell Proliferation, Cell Survival, Cells, Cultured, Cytokines, Dendritic Cells, Down-Regulation, Epitopes, Immunity, Inflammation, Inflammation Mediators, Interferon-gamma, Mice, Mice, Inbred C57BL, Mice, Knockout, Nitric Oxide, Nitric Oxide Synthase Type II, Programmed Cell Death 1 Receptor, Th1 Cells, Toll-Like Receptors, Up-Regulation, West Nile Fever, West Nile virus
Abstract

Using NOS2 KO mice, we investigated the hypothesis that NO modulation of BM-DC contributes to the NO-mediated control of Th1 immune responses. BM-DCs from NOS2 KO mice, compared with WT BM-DCs, have enhanced survival and responsiveness to TLR agonists, develop more Ly6C(hi)PDCA1(+) DCs that resemble inflammatory DCs and produce high levels of inflammatory cytokines. Also, compared with WT-infected mice, NOS2 KO mice infected with WNV showed enhanced expansion of a similar inflammatory Ly6C(hi)PDCA1(+) DC subset. Furthermore, in contrast to WT DCs, OVA-loaded NOS2 KO BM-DCs promoted increased IFN-γ production by OTII CD4(+) T cells in vitro and when adoptively transferred in vivo. The addition of a NO donor to NOS2 KO BM-DCs prior to OTII T cells priming in vivo was sufficient to revert Th1 immune responses to levels induced by WT BM-DCs. Thus, autocrine NO effects on maturation of inflammatory DCs and on DC programming of T cells may contribute to the protective role of NO in autoimmune diseases and infections. Regulating NO levels may be a useful tool to shape beneficial immune responses for DC-based immunotherapy.

DOI10.1189/jlb.0610329
Alternate JournalJ. Leukoc. Biol.
PubMed ID21178115